Land: Den Europæiske Union
Sprog: engelsk
Kilde: EMA (European Medicines Agency)
Synthetic peptide analogue of GnRF conjugated to diptheria toxoid
Zoetis Belgium SA
QI09AX
Gonadotropin releasing factor (GnRF) analogue-protein conjugate
Male pigs (from 8 weeks of age); Female pigs (from 14 weeks of age)
Immunologicals for suidae
Male pigs:Induction of antibodies against GnRF to produce a temporary immunological suppression of testicular function. For use as an alternative to physical castration for the reduction of boar taint caused by the key boar taint compound androstenone, in entire male pigs following the onset of puberty. Another key contributor to boar taint, skatole, may also be reduced as an indirect effect. Aggressive and sexual (mounting) behaviours are also reduced.Female pigs:Induction of antibodies against GnRF to produce a temporary immunological suppression of ovarian function (suppression of oestrus) in order to reduce the incidence of unwanted pregnancies in gilts intended for slaughter, and to reduce the associated sexual behaviour (standing oestrus).
Revision: 20
Authorised
2009-05-11
18 B. PACKAGE LEAFLET 19 PACKAGE LEAFLET: IMPROVAC SOLUTION FOR INJECTION FOR PIGS 1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT Marketing authorisation holder and manufacturer responsible for batch release: Zoetis Belgium SA Rue Laid Burniat 1 1348 Louvain-la-Neuve BELGIUM 2. NAME OF THE VETERINARY MEDICINAL PRODUCT Improvac solution for injection for pigs 3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S) One dose (2 ml) contains: ACTIVE SUBSTANCE: Gonadotropin releasing factor (GnRF) analogue-protein conjugate min. 300 µg. (a synthetic peptide analogue of GnRF conjugated to diphtheria toxoid) ADJUVANT: Diethylaminoethyl (DEAE)-Dextran, an aqueous, non-mineral oil-based adjuvant 300 mg. EXCIPIENT: Chlorocresol 2.0 mg. 4. INDICATION(S) Male pigs: Induction of antibodies against GnRF to produce a temporary immunological suppression of testicular function. For use as an alternative to physical castration for the reduction of boar taint caused by the key boar taint compound androstenone, in entire male pigs following the onset of puberty. Another key contributor to boar taint, skatole, may also be reduced as an indirect effect. Aggressive and sexual (mounting) behaviours are also reduced. The onset of immunity (induction of anti-GnRF antibodies) can be expected within 1 week post second vaccination. Reduction of androstenone and skatole levels has been demonstrated from 4 to 6 weeks post second vaccination. This reflects the time needed for clearance of boar taint compounds already present at the time of vaccination as well as the variability of response between individual animals. Reduction of aggressive and sexual (mounting) behaviours can be expected from 1 to 2 weeks post second vaccination. Female pigs: Induction of antibodies against GnRF to produce a temporary immunological suppression of ovarian function (suppression of oestrus) in order to reduce the incidence of unwanted pregnancies in gilts Læs hele dokumentet
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Improvac solution for injection for pigs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One dose (2 ml) contains: ACTIVE SUBSTANCE: Gonadotropin releasing factor (GnRF) analogue-protein conjugate min. 300 μg. (a synthetic peptide analogue of GnRF conjugated to diphtheria toxoid) ADJUVANT: Diethylaminoethyl (DEAE)-Dextran, an aqueous, non-mineral oil-based adjuvant 300 mg. EXCIPIENT: Chlorocresol 2.0 mg. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Solution for injection. 4. CLINICAL PARTICULARS 4.1 TARGET SPECIES Male pigs (from 8 weeks of age). Female pigs (from 14 weeks of age). 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES Male pigs: Induction of antibodies against GnRF to produce a temporary immunological suppression of testicular function. For use as an alternative to physical castration for the reduction of boar taint caused by the key boar taint compound androstenone, in entire male pigs following the onset of puberty. Another key contributor to boar taint, skatole, may also be reduced as an indirect effect. Aggressive and sexual (mounting) behaviours are also reduced. The onset of immunity (induction of anti-GnRF antibodies) can be expected within 1 week post second vaccination. Reduction of androstenone and skatole levels has been demonstrated from 4 to 6 weeks post second vaccination. This reflects the time needed for clearance of boar taint compounds already present at the time of vaccination as well as the variability of response between individual animals. Reduction of aggressive and sexual (mounting) behaviours can be expected from 1 to 2 weeks post second vaccination. Female pigs: Induction of antibodies against GnRF to produce a temporary immunological suppression of ovarian function (suppression of oestrus) in order to reduce the incidence of unwanted pregnancies in gilts intended for slaughter, and to reduce the associated sexual behaviour (standing oestrus). The onset of Læs hele dokumentet